A study of NCAA Division I college football games found a significant association between the performance of away teams and both their direction of travel and t
Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
Data highlight the clinical effectiveness of WAKIX for excessive daytime sleepiness and cataplexy in adults with narcolepsy
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ Harmony Biosciences Holdings, Inc. ( Harmony ) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat (NNT) and effect sizes for treatment with WAKIX
® (pitolisant) that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The poster was presented at the 35
Sleep medicine physician and sleep researcher Dr. Charlene Gamaldo of Johns Hopkins Medicine is the recipient of the inaugural Diversity, Equity and Inclusion Leadership Award from the Associated Professional Sleep Societies, LLC, a joint initiative of the American Academy of Sleep Medicine and the Sleep Research Society.
Idorsia Pharmaceuticals Ltd: Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021 2021
Idorsia Ltd (SIX: IDIA) today announced that nine abstracts for daridorexant, the company s investigational dual orexin receptor antagonist for the treatment of adults with insomnia, will be presented at SLEEP 2021. The annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society is conducted virtually from June 10-13.
Antonio Olivieri, Senior Vice President
, Head of Global Medical Affairs
of Idorsia commented: As a company with a strong scientific core rooted in innovative small molecules, Idorsia aims to transform the horizon of therapeutic options. We look forward to presenting new data from our Phase 3 clinical program and other important new data on daridorexant. This reflects our commitment to advance research for insomnia, a condition that can substantially impact the physical and mental health of patients and remains an ar
Jazz shares results from sleep medicine research and the development of novel therapeutic options for people living with sleep disorders DUBLIN, June 9, 2021 /PRNewswire/ Jazz Pharmaceuticals